Assertio Q1 net product sales $26.0M (-18% YoY), GAAP loss $13.5M; settles DOJ qui tam, transfers opioid liabilities

Assertio Holdings, Inc.

2025-Q1 EPS reported -$0.14 revenue$26,488,000

Net product sales $26.0M vs $31.9M YoY; GAAP net loss $13.5M ($0.14 loss per share) vs $4.5M loss.
Adjusted EBITDA $0.2M vs $7.4M YoY; adjusted EPS ($0.04) vs $0.04 positive.
Rolvedon net sales $13.1M (-10% YoY) on lower pricing; Indocin $5.5M (-37% YoY) on generic competition.
Settled DOJ False Claims Act lawsuit and last Glumetza antitrust action; transferred subsidiary with opioid liabilities.
Cash $87.3M; $40M in 6.5% convertible notes due 2027; no near-term maturities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.